SecBot SecBot
PRESS-RELEASE ·Filed Nov 2, 2026

KRYS

Krystal Biotech, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed14d 15h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Monitor upcoming clinical catalysts: KB111 interim HHD data before year-end, KB803 top-line results in February 2027, and KB801 NK trial enrollment progress. The $400M buyback authorization provides downside support but execution is discretionary.

DirectionBullish
Confidencehigh
Horizonweeks

KB113

● Neutral Named in this press release
Impact
Phase
Pilot study (proof-of-concept, equivalent to early Phase 1/2)
Time to market
KB113 is in early-stage development with no registered Phase 2/3 trial and no defined regulatory timeline. The company is in discussions with the FDA to determine the clinical development plan. If a pivotal program is agreed upon and initiated in 2027, potential approval would likely be several years away, barring a breakthrough or accelerated pathway.
Next catalyst
None dated

What to watchWatch for Krystal Biotech's announcement of FDA alignment on KB113's clinical development plan, which will define whether the program advances into a registrational trial or requires additional dose-finding studies. The small pilot (n=3) provides proof-of-concept but the regulatory path and timeline remain undefined, making KB113 a pipeline story rather than a near-term catalyst.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$295.90
T+0 close · Nov 2, 2026 · via day close
Latest settled
+2.42%
T+5 · $303.06 · next T+20 in 14d
Vs SPY
+2.34%
α at T+5
Latest observation
+3.08%
T+9 · FF3 residual α
  1. T+0 · Nov 2 $295.90entry
  2. T+1 · 14d ago +3.09%α +2.79% · $305.03
  3. T+5 · 8d ago +2.42%α +2.34% · $303.06
  4. T+10 · todayOpen
  5. T+20 · in 14d Pending
  6. T+60 · in 2mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Krystal Biotech reported Q3 2026 VYJUVEK revenue of $127.3M, up 30% YoY and above the $126.5M consensus. GAAP diluted EPS of $2.05 beat the $1.92 consensus. The company also authorized a $400M share repurchase program and provided positive KB113 clinical data in Gorlin syndrome.

Key Financial Metrics

EPS
$2.05
est $1.92 · +6.8%
Revenue
$127.3M
est $126.5M · +0.7% · +30.2% YoY
Rating
beat
Gross Margin
94%

Key Facts

  • Q3 2026 VYJUVEK net product revenue of $127.3M, up 30% YoY from $97.8M
  • GAAP diluted EPS of $2.05, above consensus estimate of $1.92
  • Gross margin of 94% for the quarter
  • Board authorized share repurchase program of up to $400 million
  • KB113 clinical data showed >80% of assessed BCC lesions with clinical regression in Gorlin syndrome patients
  • Cash and investments of $1.2 billion at quarter end
  • FY 2026 non-GAAP combined R&D and SG&A expense guidance of $155M-$165M

Financial Impact

Revenue beat consensus by $0.8M (0.6%), EPS beat consensus by $0.13 (6.8%)

revenueepscash position

Risk Factors

  • KB801 enrollment slower than expected due to narrow eligibility criteria and placebo-controlled design
  • Net income declined 21% YoY due to higher income tax expense ($17.1M vs $31.4M benefit)
  • Share repurchase program has no expiration and does not obligate repurchases
  • Pricing negotiations in France not expected until at least 2027

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3392990

Track record

18 reports on KRYS

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +26.60% at T+60 after the May 4, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 2, 202614d ago 8-K Bullish 6/10 No price data
  2. Nov 2, 202614d ago Press Release Bullish 6/10 Viewing Entry $295.90 Now $297.90 +0.68% settles Dec 1
  3. Oct 30, 202617d ago SC 13G/A Bearish 5/10 Entry $332.29 Now $297.90 +10.35% settles Nov 30
  4. Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $321.42 Now $297.90 −7.32% settles Nov 25
  5. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $321.42 Now $297.90 −7.32% settles Nov 25
  6. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $320.13 Now $297.90 −6.94% settles Nov 19
  7. Oct 21, 202626d ago Institutional Cluster Neutral 3/10 Entry $320.13 Now $297.90 −6.94% settles Nov 19
  8. Oct 15, 20264w ago 8-K Bullish 6/10 Entry $330.00 to $305.68 Now $297.90 −9.73% ▼ −7.37% −5.47% vs SPY
  9. Sep 4, 202610w ago Insider Cluster Bearish 5/10 Entry $351.26 to $326.81 Now $297.90 +15.19% ▲ +6.96% +8.67% vs SPY
  10. Aug 14, 202613w ago 144 Neutral 2/10 Entry $335.73 to $336.68 Now $297.90 −11.27% ▲ +0.28% +2.26% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens Wed (10h 28m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026